Secret History: Return of the Black Death Channel 4, 7-8pm In 1348 the Black Death swept through London, killing people within days of the appearance of their first symptoms. Exactly how many died, and why, has long been a mystery. This Secret History documentary follows experts as they pick through the evidence and reveal why the plague killed on such a scale. And they ask, what might be coming next?

Medscape

Objective: The long-term efficacy and safety of responsive direct neurostimulation was assessed in adults with medically refractory partial onset seizures. Methods: All participants were treated with a cranially implanted responsive neurostimulator that delivers stimulation to 1 or 2 seizure foci via chronically implanted electrodes when specific electrocorticographic patterns are detected (RNS System). Participants had completed a 2-year primarily open-label safety study (n = 65) or a 2-year randomized blinded controlled safety and efficacy study (n = 191); 230 participants transitioned into an ongoing 7-year study to assess safety and efficacy. Results: The average participant was 34 (±11.4) years old with epilepsy for 19.6 (±11.4) years. The median preimplant frequency of disabling partial or generalized tonic-clonic seizures was 10.2 seizures a month. The median percent seizure reduction in the randomized blinded controlled trial was 44% at 1 year and 53% at 2 years ( p p Conclusions: The RNS System is the first direct brain responsive neurostimulator. Acute and sustained efficacy and safety were demonstrated in adults with medically refractory partial onset seizures arising from 1 or 2 foci over a mean follow-up of 5.4 years. This experience supports the RNS System as a treatment option for refractory partial seizures. Classification of evidence: This study provides Class IV evidence that for adults with medically refractory partial onset seizures, responsive direct cortical stimulation reduces seizures and improves quality of life over a mean follow-up of 5.4 years.

/pdf/long-term-treatment-with-responsive-brain-stimulation-in-2e8p9h0527.pdf

Long-term treatment with responsive brain stimulation in adults with refractory partial seizures

The burden of comorbidity in people with epilepsy is high. Several diseases, including depression, anxiety, dementia, migraine, heart disease, peptic ulcers, and arthritis are up to eight times more common in people with epilepsy than in the general population. Several mechanisms explain how epilepsy and comorbidities are associated, including shared risk factors and bidirectional relations. There is a pressing need for new and validated screening instruments and guidelines to help with the early detection and treatment of comorbid conditions. Preliminary evidence suggests that some conditions, such as depression and migraine, negatively affect seizure outcome and quality of life. Further investigation is needed to explore these relations and the effects of targeted interventions. Future advances in the investigation of the comorbidities of epilepsy will strengthen our understanding of epilepsy and could play an important part in stratification for genetic studies.

/pdf/comorbidities-of-epilepsy-current-concepts-and-future-4qxfz5yqwt.pdf

Comorbidities of epilepsy: current concepts and future perspectives.

https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(12)61455-X.pdf

Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan

SummaryObjective
There is not yet a clear consensus on the incidence of sudden unexpected death in epilepsy (SUDEP) or the extent of its burden on public health. In this systematic review, we seek to summarize the incidence of SUDEP and its age distribution, as well as the years of potential life lost and cumulative risks of SUDEP for persons with epilepsy.

Methods
We conducted a systematic search for epidemiologic studies of sudden death in epilepsy and rated their quality of evidence. We pooled data from comparable higher quality population-based studies of SUDEP incidence across all age groups, calculating the overall incidence of SUDEP per 100,000 population, and per 1,000 people with epilepsy. Using standard formulas, we also calculated the years of potential life lost and cumulative risks associated with SUDEP.

Results
SUDEP has an estimated overall crude annual incidence rate of 0.81 cases per 100,000 population, or 1.16 cases per 1,000 patients with epilepsy. Comparing years of potential life lost from SUDEP with selected other neurologic diseases, SUDEP ranks second only to stroke.

Significance
Despite limitations to the data on which our analysis is based, we conclude that the public health burden of SUDEP, which has previously been underappreciated, is substantial and deserves much more attention from clinicians, researchers, and the public health community.

A PowerPoint slide summarizing this article is available for download in the Supporting Information section here.

https://onlinelibrary.wiley.com/doi/pdf/10.1111/epi.12666

Sudden unexpected death in epilepsy: assessing the public health burden.

Epilepsy across the spectrum: promoting health and understanding. A summary of the Institute of Medicine report.

Epilepsy Across the Spectrum

Committee on the public health dimensions of the epilepsies

/pdf/summary-a-reprint-from-epilepsy-across-the-spectrum-3ofyoxom9w.pdf

Andrea M Schultz

Papers

Epilepsy across the spectrum: promoting health and understanding. A summary of the Institute of Medicine report.

Epilepsy Across the Spectrum

Committee on the public health dimensions of the epilepsies

Summary: a reprint from epilepsy across the spectrum: promoting health and understanding.

Testimonies submitted for the Institute of Medicine report: epilepsy across the spectrum: promoting health and understanding.